ROSEN LAW FIRM Urges Altimmune, Inc. Investors to Act Before Deadline in Class Action Lawsuit

New York City-based Rosen Law Firm, renowned for its advocacy for investor rights, is issuing a reminder to all investors who purchased securities from Altimmune, Inc. ALT between December 1, 2023, and April 26, 2024. These investors are urged to connect with counsel prior to the approaching July 5, 2024 deadline regarding the securities class action initiated against the biopharmaceutical company.

The Allegations

During the specified period, known as the Class Period, Altimmune, Inc., headquartered in Gaithersburg, Maryland, is alleged to have disseminated information that was materially misleading to shareholders. This company, primarily engaged in developing intranasal vaccines and treatments for liver disease, is now facing legal scrutiny for its actions during this time which may have impacted investor decisions.

Legal Recourse and Class Action Details

Investors who have been affected by the actions of Altimmune, Inc. have a rapidly closing window to join the class action lawsuit as a lead plaintiff. The deadline, set for July 5, 2024, is critical for those who have suffered losses to become a part of the legal proceedings. Rosen Law Firm is facilitating the process for aggrieved investors to assert their rights and is ready to provide the necessary legal counsel.

By joining the class action, affected investors are aiming to recover damages and hold Altimmune, Inc. accountable for the alleged misrepresentations that have potentially influenced the investment market surrounding the ALT ticker.

Investor's Call to Action

Rosen Law Firm encourages those who have acquired Altimmune, Inc. securities during the Class Period and incurred losses to seek legal representation. The importance of the July 5, 2024 lead plaintiff deadline cannot be overstressed, as it is a pivotal point for investors to join the class action and assert their claims.

RosenLaw, Altimmune, Deadline